论文部分内容阅读
目的探讨CCR4在肺腺癌组织中的表达与临床病理特征及预后的关系。方法收集肺腺癌手术存档资料629例,癌旁正常肺组织50例和肺炎性假瘤样增生组织50例作为对照,采用免疫组化法检测肺腺癌及对照组织中CCR4的表达情况。采用实时荧光PCR法对629例肺腺癌患者进行EGFR 18-21外显子基因突变检测,并进行随访。结果 (1)CCR4在肺腺癌组织中的表达高于癌旁正常肺组织及肺炎性假瘤样增生组织,差异显著(P<0.05);(2)CCR4的表达与患者TNM分期、淋巴结转移、病理分级、肿瘤大小、EGFR突变、胸膜受侵均有相关性(P<0.05);(3)经Kaplan-Meier生存分析结果显示,肺腺癌患者12、24、36个月的累积生存率,CCR4高表达组明显低于低表达组(P<0.05);经COX多因素生存分析结果显示,患者CCR4的高表达、病理分级高级别组是肺腺癌患者生存状况的独立危险因素(P<0.05)。结论 CCR4在肺腺癌组织中的表达高于癌旁及炎性假瘤样增生组织,其表达与患者TNM分期、淋巴结转移、病理分级、肿瘤大小、EGFR突变、胸膜受侵均有关。CCR4高表达患者生存率低,CCR4是肺腺癌患者生存状况的独立危险因素。
Objective To investigate the expression of CCR4 in lung adenocarcinoma and its relationship with clinicopathological features and prognosis. Methods 629 cases of lung adenocarcinoma, 50 cases of adjacent normal lung tissue and 50 cases of inflammatory pseudotumor-like hyperplasia were collected as control. The expression of CCR4 in lung adenocarcinoma and control tissues was detected by immunohistochemistry. Real-time fluorescent PCR was used to detect 629 cases of lung adenocarcinoma patients EGFR 18-21 exon gene mutation, and were followed up. Results (1) The expression of CCR4 in lung adenocarcinoma tissues was significantly higher than that in adjacent normal lung tissues and pneumococcal pseudotumor hyperplasia tissues (P <0.05). (2) The expression of CCR4 was positively correlated with TNM stage, lymph node metastasis (P <0.05). (3) The Kaplan-Meier survival analysis showed that the cumulative survival rates of patients with lung adenocarcinoma at 12, 24, and 36 months (P <0.05). The multivariate survival analysis showed that the high expression of CCR4 and the high grade of pathological grade were the independent risk factors for the survival of patients with lung adenocarcinoma (P <0.05). Conclusion The expression of CCR4 in lung adenocarcinoma is higher than that in paracancer and inflammatory pseudotumor-like hyperplasia. The expression of CCR4 is correlated with TNM stage, lymph node metastasis, pathological grade, tumor size, EGFR mutation and pleural invasion. CCR4 high expression in patients with low survival rate, CCR4 is an independent risk factor for the survival of patients with lung adenocarcinoma.